Intrahepatic cholangiocarcinoma subtypes!
Large duct (LD) and small duct (SD) intrahepatic cholangiocarcinoma (iCCA) exhibit distinct molecular, histopathological, and clinical characteristics, with LD-iCCA often associated with KRAS and TP53 mutations, while SD-iCCA frequently harbors IDH1/2 mutations and FGFR2 fusions.
Preclinical models that accurately recapitulate the molecular and clinical differences between LD-iCCA and SD-iCCA remain limited.
Accurate subtype diagnosis is essential for guiding personalized treatment strategies in iCCA patients.
Targeted therapies and immunotherapies tailored to the genetic aberrations of LD-iCCA and SD-iCCA have the potential to revolutionize treatment outcomes.
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00008-5
